Browser does not support script.
Our research's aim is targeting DNA repair for personalized cancer therapy.
-- Dr Srinivasan Madhusudan, Head of Translational DNA Repair Group
Chemotherapy and radiation are commonly used to treat cancer. However many tumours are resistant to such treatments because cancer cells are able to counteract the effects of therapy by utilising the DNA repair machinery to repair DNA damage induced by these agents. The focus of our research is to block DNA repair in cells and thereby enhance cancer cell death. This will lead to better response to treatments and improve patient outcomes.
We are developing new biomarkers to predict who will respond to therapy and who will not.
We are developing new drugs to block DNA repair and increase cancer cell kill.
National Cancer Research Institute (NCRI) Prize 2012 - Dr Rachel Abbotts
Dr Rachel Abbotts, MRC Clinical Research Fellow at the Academic Unit of Oncology, MOL has won the National Cancer Research Institute (NCRI) Prize for 2012. Rachel has been recognised for her excellent work on APE1 manipulation in PTEN/RAD51 deficient melanoma systems for synthetic lethality application.
Breast Cancer Campaign award to study resistance to breast cancer treatment
Goulstonian Lectureship 2011 - Dr Srinivasan Madhusudan
Overcoming resistance to cancer treatment
New hope for better treatment for a rising cancer
More publications
More Cancer & Stem Cells news
PhD opportunities
Group members
The University of Nottingham Division of Oncology, School of Medicine Hucknall Road, Nottingham NG5 1PB, UK
telephone: +44 (0) 115 82 31850 email:srinivasan.madhusudan@nottingham.ac.uk